WELCOME to Stu's Views and MS News

Key-Note: Our live MS educational seminars average 65 people per educational program. SINCE our first program in February 2010, we have hosted more than 120 educational programs.

Register at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org

WATCH OUR Multiple Sclerosis archived MS EDUCATIONAL VIDEOS by Topic. Click: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information

Scroll to view all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.


Tuesday, November 25, 2014

Lights, Camera, TAKE ACTIONS NOW on MS -- Webcast with actress Madeleine Stowe

Register and have an opportunity to ask a question during this live event. See all the information showing below


For more Information or to Register
or Call - 1-866-703-6293


Synopsis of presentation by Jack Burks, MD on I “Emerging MS Therapies” and “Invisible MS Symptoms”, November 8 2014

Emerging MS Therapies plus Lemtrada- FDA approval Update

Dr Burks reviewed over 30 potential new therapies which are in the process of being tested for people with MS. They included:
      Stem cell research for MS reveals considerable interest and preliminary results that demonstrate the ability to generate stem cells from bone marrow, fat tissue and skin tissue that have the potential to help restore damaged MS brain, including myelin. Clinicals trials are ongoing. However, we must await the results of these trials and FDA approval before commercial use. Foreign “Stem cell cures for MS” Centers are not recommended because of lack of knowledge, acceptable clinical trial data, and regulations to assure safety and efficacy.
       Lemtrada (Alemtuzumab) has been recently FDA approved for relapsing forms of MS. Dr Burks reviewed the superior efficacy data compared to a FDA approved Interferon, the convenience of needing only 5 IV treatments (on consecutive days) in the first year and the caution of adverse events that necessitate close monitoring.

        Plegridy has also been recently approved by the FDA for relapsing MS. It is effective and safe, while only requiring a subcutaneous injection once every two weeks. The side effects are similar to other interferons given subcutaneously.

       Many other treatments are being tested. Most are aimed at reducing the MS damage in the Central Nervous System (CNS).Examples include:
1.      Monoclonal antibodies that target “B lymphocytes”, instead of the “T lymphocytes”. This approach attacks another part of the immune system that may damage the CNS.
2.      Vaccine type medications
3.      Medications that are already FDA approved for relapsing MS are now being tested in non-relapsing progressive forms of MS (SPMS and PPMS)
4.      Estrogen type hormone therapy for women to decrease brain damage
5.      Monoclonal antibodies that target newly recognized “T lymphocytes” which initiate inflammation.
6.       Medications similar to currently approved MS therapies, but which may have fewer side effects
7.      Medications that may reduce degeneration of brain cells, not just inflammation
8.      Medications that have been used in other diseases are being “repurposed” to treat MS.
9.      Medications to increase myelin that has been damaged
10.  Vitamin D is being studied to better determine its potential usefulness in MS
11.  A low salt diet is another method to reduce inflammation in MS
12.  Re-equilibrating the bacteria in the intestines is another novel approach to MS therapy that is just now beginning to be explored (Microbiomes)

In summary, many new potential treatments are becoming available and more are in the early stages of testing. Many of these new medications are targeting the progressive forms of MS, as well as relapsing MS.

The future for MS therapy has never looked brighter.
To watch this presentation, click here

 Keep CURRENT with MS Views and News - OPT-IN here


Biogen’s Tecfidera Label Updated After Rare Brain Infection Case

  Nov 25, 2014 

The label for Biogen Idec Inc. (BIIB)’s multiple sclerosis drug Tecfidera will be updated with information about a patient who died of a rare brain infection while taking the medicine, U.S. regulators said today.
The drug label, which gives doctors and patients information about the drug, will now detail a case of progressive multifocal leukoencephalopathy, or PML, the Food and Drug Administration said. Biogen originally disclosed the patient’s death in October, while discussing third-quarter financial results.
Tecfidera was Cambridge, Massachusetts-based Biogen’s top-selling drug in the third quarter, earning $787 million. Analysts said last month that the death wasn’t a cause for major concern, since 100,000 patients have already been treated with Tecfidera without developing PML.

The patient who died had a very low white blood cell count, which can weaken the immune system and increase the risk of PML, according to the FDA. The agency has recommended that physicians monitor Tecfidera patients’ white blood cell counts.

 Keep CURRENT with MS Views and News - OPT-IN here


IMPACT of MS on the Family and Employment - For those Affected by Multiple Sclerosis & living within Driving Distance to Columbia S.C. - for a Saturday program

THE IMPACT of MS On the Family and Work Environment
  plus - Discussion on the (11) Current MS Treatment Options 

RSVP required (see below)


To Register to attend this event, please click here


Yes, I KNOW about Veritgo... `Stuart

Stop Spinning
Feeling like you just got off an amusement park ride? You’re not alone. 

Learn about vertigo >>    

 Keep CURRENT with MS Views and News - OPT-IN here


MS Spasticity: How Do Pharmaceuticals Stack Up Against Medical Marijuana?

With more states approving the use of medical marijuana, we examine current therapies for spasticity caused by MS and compare them to Sativex, a cannabis derivative in phase III trials that’s been fast-tracked by the FDA.
Written by Jeri Burtchell | Published on November 10, 2014

How Do MS Pharmaceuticals Stack Up Against Medical Marijuana?
Oregon, Alaska, and Washington, D.C., voted in favor of legalizing marijuana last Tuesday, bringing the number of states that have decriminalized the drug or made special provisions for medicinal use to 23 (plus the District of Columbia). For people who suffer from conditions like cancer, Parkinson’s disease, seizures, or multiple sclerosis (MS) this news could bring relief. Medical marijuana is another tool in a doctor’s arsenal to help these patients fight their personal battles.
Research on the use of marijuana to treat symptoms of MS has been limited, but some studies in the past decade have shown that marijuana relieves MS spasticity.

What Is Spasticity?

According to the National MS Society, spasticity refers to muscle spasms and feelings of stiffness. It is a common symptom in people who have MS.
Medical marijuana
When MS damages the nerves that control muscles, it can result in spasticity that impairs movement and causes pain and stiffness. It usually occurs in the legs and can draw them up toward the body with painful cramping or cause spasms in the lower back.
For some patients who have muscle weakness, spasticity can be beneficial to a degree, as it provides them with the stiffness needed to walk. But when it gets out of control and the pain becomes too much to bear, it may be time to consider medication.
Dr. Vijayshree Yadav has studied the use of alternative medicine in MS for many years. In 2011, she wrote, “In a review of six controlled studies evaluating a combination of THC and CBD [the active ingredients in cannabis] for spasticity in MS, it was found that THC–CBD was well tolerated and improved patient self-reports of spasticity.”
Earlier this year, Yadav authored a set of guidelines for the American Academy of Neurology, saying that pill and mouth spray forms of cannabis have shown success in treating spasticity and bladder symptoms in MS patients.

Treatment Options for Spasticity

There are just three medications that have been approved by the U.S. Food and Drug Administration (FDA) specifically to relieve MS spasticity: Zanaflex, Baclofen, and Botox. Many other medications are used off-label to treat spasticity, too. The following sections outline how each of them works, how they are taken, and their possible side effects.
Added to this lineup is an oral spray called Sativex, which contains a derivative of medical marijuana. It is made by GW Pharmaceuticals and is available by prescription in 15 countries to treat MS spasticity. In April of this year, the FDA fast-tracked Sativex in the United States. Currently in phase III trials, it may soon be another FDA-approved choice for people with spasticity to consider.
 Continue reading

 Keep CURRENT with MS Views and News - OPT-IN here


Anti-Inmflamatory Boost from Healthline

Muffin Mania

The ginger in these fall-inspired muffins can help with your MS inflammation. 

Get baking >> 

 Keep CURRENT with MS Views and News - OPT-IN here


Take Action! Preserve Access To Stem Cell Therapy In The U.S.

Graphics by William Jones and Chelsea Henderson, Lamar University Press
Graphics by William Jones and Chelsea Henderson, Lamar University Press
Your Urgent Help Needed! New FDA Draft Guidance on Physician use of Platelets and Stem Cells Seeks to Drastically Limit What Physicians can do to Help Their Patients
The public has the opportunity until Dec 22, 2014 to present comments to the FDA regarding regulation of adult stem cells.
You can jump to the TAKE ACTION INSTRUCTIONS below, but here’s the situation.
Patients For Stem Cells opposes this draft exemption in its current form because it further limits access to use of autologous (your own) stem cells to treat illness and injury. Many of our members have found cellular medicine to be safe and effective. Further government restrictions are not needed.

 Keep CURRENT with MS Views and News - OPT-IN here


Monday, November 24, 2014

Prescription Assistance Programs for MS Disease-Modifying Therapies

The MSAA fortunately obtained the information found in this listing. Without their compilation of this information, we would not have been able to provide this to you. I would like to thank the MSAA  for putting together this up-to-date listing as this information is needed by many.

As per the MSAA, the information in this listing has been gathered from each pharmaceutical company separately and may be subject to change. For program specifics, please contact the corresponding patient services program.

To read the information found in this report, please click here

 Keep CURRENT with MS Views and News - OPT-IN here


Ocrelizumab is being studied in RRMS and in primary-progressive MS (PPMS)

Experimental Medications: Monoclonal Antibody Medications


Company: Genentech and Roche Pharma AG
  • Administered via intravenous infusion
  • Ocrelizumab is being studied in RRMS and in primary-progressive MS (PPMS)

Like Rituxan, this drug is an anti-CD20 monoclonal antibody. It has the potential advantage of being a more humanized antibody than Rituxan. As noted in the introduction to this section, humanized monoclonal antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibodies produced naturally in humans. "More humanized" refers to a protein sequence that is more similar to antibodies produced in humans, compared to another humanized monoclonal antibody (Rituxan in this instance).

In a Phase II study of ocrelizumab41 in 220 individuals with RRMS, reductions in the total number of brain lesions detected by MRI scans (the primary endpoint of the study) were highly significant at 96 percent for 2,000-mg ocrelizumab and 89 percent for 600 mg compared to placebo. The annualized relapse rate was significantly lower versus placebo at week 24, with a reduction of 73 percent for ocrelizumab 2,000 mg, and 80 percent for ocrelizumab 600 mg. Ocrelizumab's effectiveness was maintained through week 72 (about two weeks less than one year and five months); the proportion of relapse-free patients at week 72 was 84 percent for the 600-mg group, and 82 percent for the 2,000-mg ocrelizumab group.

Infusion-related symptoms, which were generally mild to moderate, were seen in the ocrelizumab-treated groups. The number of serious adverse events was small and similar among the groups. However, one patient in the ocrelizumab 2,000-mg group died of a systemic inflammatory response of unknown etiology (e.g., the reason why this response occurred is not known). Although Phase III trials in rheumatoid arthritis had significant rates of serious and opportunistic infections, none were identified in this trial of 220 people with MS. Please note that the number of MS patients studied in this Phase II trial is small in comparison to the number of rheumatoid arthritis patients studied in the larger Phase III studies that have already been completed.
Several Phase III trials of ocrelizumab are now underway. OPERA I42 and II43 are comparing ocrelizumab (600 mg) to Rebif (44 mcg of interferon beta-1a given via subcutaneous injection three times per week) in RRMS and plan to enroll approximately 800 patients in each study. These trials are anticipated to run through mid-2015. The primary outcome measure is annualized relapse rate; secondary measures include time to onset of sustained disability progression, the proportion of relapse-free patients, MRI measures of disease activity, and change in Multiple Sclerosis Functional Composite (MSFC) scale, which measures upper and lower limb function as well as cognition.

In addition, because subgroup analysis of Rituxan in the OLYMPUS study suggested a benefit to younger PPMS patients and those with gadolinium-enhancing lesions, ocrelizumab is also being studied in primary-progressive MS (PPMS). The Phase III ORATORIO44 safety and efficacy study of ocrelizumab in 630 patients with PPMS is currently recruiting participants.
Patients will receive either ocrelizumab (300 mg given intravenously in two infusions separated by 14 days in each treatment cycle) or placebo. The study is scheduled to run through late 2017. The primary outcome measure is time to onset of sustained disability progression (for at least 12 weeks); secondary outcome measures include the time to sustained disability progression (for at least 24 weeks), change in the total volume of T2 lesions (as seen on MRI), as well as safety, tolerability, and the incidence of adverse events.

Article sourcing found here

 Keep CURRENT with MS Views and News - OPT-IN here


Treatment of multiple sclerosis with acupuncture

Multiple Sclerosis was once regarded in China as a very rare disease of the nervous system.  However, China has been experiencing an increasing rate of incidence of this disease in recent years, and more and more doctors tend to consider the ophthalmoneuromyelitis( the Devil Disease) to be one form of this disease.  

In this report, patients with ophthalmoneuromyelitis were all listed as confirmed cases.  Altogether 69 cases of multplesclerosis have been treated with excellent effect in recent years in our hospital by means of toning the liver and spleen, nourishing the blood to improve the acuity of vision, and strengthening the muscle and bones.  After the treatment, most of the patients gain improvement in their symptoms and some even achieved a permanent cure of the disease.

Clinical Data
Among the 69 cases, 57 belonged to confirmed cases and 12 belonged to almost confirmed cases.  25 were males and 44 females.  The ages of the patients ranged from 11-64 years old, most of whom were in their twenties.  The average age of onset was 31.
The primary symptoms in the nervous system include visual disturbance ( 20 cases), pain of the limbs and sensory disturbance ( 15 cases), weakness of the limbs ( 11 cases), pain of the limbs, sensory disturbance, and weakness ( 7 cases), facial paralysis ( 2 cases), double vision ( 2 cases), lallation ( 2 cases), urinary incontinence plus headache ( 2 cases), and one case, respectively, for tremor, walking disturbance, tinnitus, dizziness, dysphagia, and disorder of consciousness.
From the above table, it can be seen that among the total 69 cases of muultiplesclerosis, there are 21 cases ( 30.43%) mainly with symtoms in the spinal cord and 48 cases ( 69.57%) with symptoms both in the spinal cord and in the optic nerve.  The primary onset cases were 39 ( 56.53%) and those  with more than two onsets were 30 ( 43.47%).

Criteria of the Diagnosis

All of the patients were diagnosed with the following criteria.

Clinical confirmation

Symptoms and signs indicate one or more foci in the nervous system which affect the predilection sites for multiple sclerosis, such as optic nerve, spinal cord, brain stem, etc.
In the whole process of disease, there are remarkable remittances and relapses, or the disease is with a stepladder development. Examinations were made to exclude such pathogenic factors as tumor, angionosis, cervical spondylosis, or diseases in the cerebellum.

Therapeutic method
According to TCM theory, this disease is considered to be caused by insufficient Kidney-Yin.  Deficiency of Qi and Blood and lack of nutrition to the eyes which leads to blurred vision or even blindness: " The Kidney is concerned with the bone and produces bone marrow." Also: " The brain is the sea of medulla." When there is an insufficient supply of nutrition to the brain due to emptiness of the medulla sea, or when there is hyperactivity of Fire due to Yin Deficiency, dizziness will be the result.  For longstanding cases, the patient will experience Insufficient Kidey-Yang and this is the reason of cold limbs and urinary incontinence.  Flaccidity syndrome often results from Deficiency of Liver-Yin and Kidney-Yin or Deficiency of Qi and Blood, and malnutrition of muscle and tendons.

Principle of the treatment

Tonifying the Liver and Kidney, nourishing the Blood to clear the eyes, and strengthening the muscles and tendons.

Therapeutic course and follow -up
The needling treatment can be given once everyday and 14 treatments constitute a therapeutic course.  Each case should have a follow-up of therapeutic courses.

It should be noted that the above analysis of the therapeutic effect is based on the clinical symptoms and signs, which may not be identical with the actual anatomical changes.  The patient may have wider pathogenic changes which cannot be found by the clinical examinations.

In this group of patients, there were 48 cases with disturbance of vision, among whom, 14 cases ( 29.16%) were nearly recovered, 32 cases ( 67.66%) were remarkably improved, and 2 cases ( 4.16%)were with slight improvement.  In the 21 cases of cranial nerve disturbance, 15 cases ( 71.43%) were basically cured; for the 34 cases with motor and sensory disturbance, 28 cases ( 82.35%) were almost cured


The present studies on the etiology and pathogenesis of multiplesclerosis show that the disease, under different geographical conditions and in different individuals, appears with the allergic reaction as the induced factor.  Much data indicate that the pathogenesis of this disease is closely related to the immunoregulatory system and the autoimmunity of the central nervous system.  As the causes of the disease are still unknown, there is still no specific therapeutic method.  In China, multiple sclerosis is shown in most cases in its variant form, i.e., the Devil Disease, with the involvement of the optic nerve and the spinal cord as the two main characteristics.  The acupuncture treatment is mainly to tonify the Kidney, Liver and Spleen, and to nourish the Blood to clear the eyes and to strengthen the bones and tendons as a supplement.  This therapeutic method is worth further study.

Symptoms in the optic nerve and in the spinal cord may appear simultaneously.  In the case when the optic nerve is involved, usually one eye is attacked first, followed by the other.  In most cases, the optic symptoms are followed by spinal symptoms.  There are also cases with a reversed order.  

Continue reading 

 Keep CURRENT with MS Views and News - OPT-IN here


Cannabidiol (CBD) is a non-psychoactive component of Cannabis that has a wide range of therapeutic benefits



This Review was created by The Healthy Report to expose the truth behind CBD oil

(Health Review) - If you haven’t already heard, Cannabidiol (CBD) is a non-psychoactive component of Cannabis that has a wide range of therapeutic benefits. CBD is naturally occurring in the Hemp plant and according to the United States own government patent #6,630,507 it supports the nutritional health of aging bodies. Canabanoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.

Some benefits scientists suggest people are getting from Cannabidiol (CBD)

  • Reduced feelings of anxiety
  • Reversing damage causes by alcohol
  • Anti-inflammatory, neuro-protective, and anti-oxidant
Continue reading this report found here: http://healthyreport.info/?aid=1356&oid=12&sid=3 

 Keep CURRENT with MS Views and News - OPT-IN here